Results 31 to 40 of about 2,051,186 (321)
Histochemical and immunohistochemical analyses of primary carcinoma of the liver. [PDF]
, 1991 Hematoxylin and eosin (H-E) stained liver sections of 47 autopsy cases of hepatic malignancies were examined. There were 43 cases of hepatocellular carcinoma (subtypes of 30 trabecular, 7 solid, 5 pseudoglandular, and one scirrhous carcinoma), 3 of ...
Hayashi, Keiki +2 more
core +1 more source
Combination immunotherapy for hepatocellular carcinoma.
Journal of Hepatology, 2023 Single-agent immune checkpoint inhibitors (ICIs) have been tested in patients with advanced hepatocellular carcinoma (HCC) showing an objective response rate of 15-20%, mostly without a significant overall survival (OS) benefit.
L. Rimassa, R. Finn, B. Sangro
semanticscholar +1 more source
Sarcoidosis-associated hepatocellular carcinoma [PDF]
, 2010 Sarcoidosis is a systemic granulomatous inflammation of unknown etiology, and seems to involve the liver parenchyma in most cases. However, sarcoidosis-associated hepatocellular carcinoma is rare. We report here a case in which a hepatocellular carcinoma
Aiko, Satoshi +7 more
core +1 more source
The Lancet, 2017 Summary Background For patients with advanced hepatocellular carcinoma, sorafenib is the only approved drug worldwide, and outcomes remain poor. We aimed to assess the safety and efficacy of nivolumab, a programmed cell death protein-1 (PD-1) immune ...
A. El-Khoueiry +20 more
semanticscholar +1 more source
A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. [PDF]
, 2015 Hepatocellular carcinoma (HCC), the second leading cause of cancer deaths worldwide, is difficult to treat and highly lethal. Since HCC is predominantly diagnosed in patients with cirrhosis, treatment planning must consider both the severity of liver ...
Busuttil, Ronald W +2 more
core +2 more sources
Clinical Liver Disease, 2019 and Scope This guidance provides a data-supported approach to the diagnosis, staging, and treatment of patients diagnosed with hepatocellular carcinoma (HCC). A guidance document is different from a guideline.
J. Marrero +7 more
semanticscholar +1 more source
Hepatocellular carcinoma: Review of disease and tumor biomarkers. [PDF]
, 2016 © The Author(s) 2016.Hepatocellular carcinoma (HCC) is a common malignancy and now the second commonest global cause of cancer death. HCC tumorigenesis is relatively silent and patients experience late symptomatic presentation. As the option for curative
Cox, IJ +8 more
core +1 more source
Microenvironment and tumor cells: two targets for new molecular therapies of hepatocellular carcinoma. [PDF]
, 2018 Hepatocellular carcinoma (HCC), is one of the most frequent human cancer and is characterized by a high mortality rate. The aggressiveness appears strictly related to the liver pathological background on which cancer develops.
Amicone, Laura, Marchetti, Alessandra
core +1 more source
Hepatology Research, 2023 The fifth version of the Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, according to the methodology of evidence‐based medicine and partly to the Grading of Recommendations Assessment ...
K. Hasegawa +26 more
semanticscholar +1 more source
Molecular Oncology, 2019 The cross‐talk between hepatic stellate cells (HSCs) and hepatic carcinoma cells contributes to hepatocellular carcinoma (HCC) progression, but the underlying mechanism is largely unknown.
Jie Li +17 more
doaj +1 more source